Royalderm Agnieszka Nawrocka — Clinical Trial Site

9 Registered trials

5 Currently recruiting

Organisation

Royalderm Agnieszka Nawrocka

Location

Warszawa, Poland

Identifier

ORL-000003480

Address

Ul. Krzysztofa Kieślowskiego 3B/3, 02-962, Poland

Departments

N/A
NA
not applicable/nie dotyczy

Clinical trials at this site (9)

Search interface

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder… Pending

2023-508329-28-00 Atopic Dermatitis 4
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting

2024-517632-22-00 Hidradenitis Suppurativa 5 2025-10-06
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Moderate to Severe Plaque Psoriasis 5 2025-09-16
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Hidradenitis Suppurativa 4 2025-03-06
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07